Description of Event or Problem · 0
IT WAS REPORTED IN AN ARTICLE (MILLER, S., WATKINS, L., MATHARU, M. LONG-TERM OUTCOMES OF OCCIPITAL NERVE STIMULATION FOR CHRONIC MIGRAINE: A COHORT OF 53 PATIENTS. THE JOURNAL OF HEADACHE AND PAIN. 2016. 17(1):68. DOI 10.1186/S10194-016-0659-0) THAT 47 PATIENTS WITH ONS FOR CHRONIC MIGRAINE SHOWED A SIGNIFICANT REDUCTION IN MEAN ANY-HEADACHE DAYS, MEAN DAILY PAIN DURATION, AND MEAN DAILY PAIN INTENSITY. ALTHOUGH A SIGNIFICANT REDUCTION OF 3.94 POINTS WAS RECORDED IN HIT-6, THE REDUCTION IN MIDAS WAS NOT SIGNIFICANT. AFFECT SCORES, EQ5D AND SF-36 COMPOSITE SCORES FAILED TO SHOW ANY IMPROVEMENT ACROSS THE COHORT, BUT THE EURO-VAS DID SHOW SIGNIFICANT IMPROVEMENT. (B)(4). THIS REPORT REFLECTS INFORMATION RECEIVED BY FDA IN THE FORM OF A NOTIFICATION PER 803.22 (B)(2).